



Vigilancia de la Poliomielitis en las Américas

Cuadro No. 1
Análisis de las muestras de heces de casos
Últimas 52 semanas (2002/25-2003/24)

| Lab. | País | Total* | SIN RESULTADOS | | | % Asla- miento | AISLAMIENTO DE ENTEROVIRUS | | | | |
|-------|------|--------|-------------------|-------------|-------------|-------------------|----------------------------|----------------------|------------|---------|---------|
| | | | Aún no en lab. | <28 Días | >28 Días | | Negativo | Otros Enterovirus | Poliovirus | | |
| | | | | | | | | | Pendiente | Vacunal | Salvaje |
| BEL | BRA | 67 | 7 | 0 | 4 | 10,7 | 50 | 6 | 0 | 0 | 0 |
| CAR | DOR | 26 | 0 | 0 | 0 | 15,4 | 22 | 4 | 0 | 0 | 0 |
| | GUY | 6 | 0 | 0 | 0 | 16,7 | 5 | 1 | 0 | 0 | 0 |
| | HAI | 8 | 0 | 0 | 0 | 25,0 | 6 | 2 | 0 | 0 | 0 |
| | HON | 54 | 3 | 2 | 0 | 34,7 | 32 | 14 | 0 | 3 | 0 |
| | JAM | 7 | 0 | 0 | 0 | 0,0 | 7 | 0 | 0 | 0 | 0 |
| | SUR | 1 | 0 | 0 | 0 | 0,0 | 1 | 0 | 0 | 0 | 0 |
| | TRT | 8 | 0 | 0 | 0 | 0,0 | 8 | 0 | 0 | 0 | 0 |
| FIO | BRA | 396 | 74 | 0 | 15 | 17,6 | 253 | 52 | 0 | 2 | 0 |
| | PER | 72 | 4 | 0 | 9 | 28,8 | 42 | 17 | 0 | 0 | 0 |
| INC | COR | 14 | 1 | 0 | 0 | 30,8 | 9 | 4 | 0 | 0 | 0 |
| | ELS | 91 | 0 | 0 | 0 | 17,6 | 75 | 16 | 0 | 0 | 0 |
| | GUT | 74 | 0 | 7 | 2 | 10,8 | 58 | 7 | 0 | 0 | 0 |
| | NIC | 22 | 0 | 0 | 0 | 22,7 | 17 | 5 | 0 | 0 | 0 |
| | PAN | 2 | 1 | 0 | 0 | 0,0 | 1 | 0 | 0 | 0 | 0 |
| INDRE | MEX | 315 | 0 | 14 | 8 | 22,2 | 228 | 61 | 0 | 4 | 0 |
| INH | VEN | 88 | 0 | 5 | 0 | 3,6 | 80 | 3 | 0 | 0 | 0 |
| INS | COL | 103 | 0 | 11 | 7 | 17,6 | 70 | 11 | 1 | 3 | 0 |
| | ECU | 29 | 0 | 0 | 0 | 10,3 | 26 | 3 | 0 | 0 | 0 |
| ISP | CHI | 25 | 0 | 2 | 1 | 4,5 | 21 | 1 | 0 | 0 | 0 |
| MAL | ARG | 111 | 0 | 3 | 0 | 15,7 | 91 | 12 | 0 | 5 | 0 |
| | BOL | 54 | 3 | 7 | 10 | 11,8 | 30 | 4 | 0 | 0 | 0 |
| | CHI | 76 | 0 | 0 | 0 | 6,6 | 71 | 3 | 0 | 2 | 0 |
| | PAR | 17 | 1 | 0 | 0 | 12,5 | 14 | 1 | 0 | 1 | 0 |
| | URU | 2 | 0 | 0 | 0 | 50,0 | 1 | 0 | 0 | 1 | 0 |
| REC | BRA | 2 | 0 | 0 | 0 | 50,0 | 1 | 0 | 0 | 1 | 0 |
| TOTAL | | 1670 | 94 | 51 | 56 | 17,0 | 1219 | 227 | 1 | 22 | 0 |

* Cada muestra se refiere a un individuo

Muestras de casos solamente

Cuadro No. 2
Poliovirus con diferenciación intratípica pendiente
Últimas 52 semanas (2002/25-2003/24)

| LAB | PAIS | POLIOVIRUS | | | | | | | | | | | | TOTAL | |
|-------|------|-------------------|----|----|------|-----------------------|----|----|------|-----------------------|----|----|------|-------|---|
| | | AÚN NO EN EL LAB, | | | | EN LAB < de 4 semanas | | | | EN LAB > de 4 semanas | | | | | |
| | | P1 | P2 | P3 | Mez. | P1 | P2 | P3 | Mez. | P1 | P2 | P3 | Mez. | | |
| COL | | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TOTAL | | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |

Muestras de casos
solamente



Vigilancia de Parálisis Flácida Aguda

Vol, 18, No 24

Cuadro No. 1
Casos de parálisis flácida aguda bajo investigación
según semana de notificación

| PAIS | TOTAL | ACUM. | Semana | | | | | | | | |
|--------------|----------|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|
| | | | 1-4 | 5-8 | 9-12 | 13-16 | 17-20 | 21 | 22 | 23 | 24 |
| ARG | 0 | 7 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 2 |
| BOL | 0 | 20 | 0 | 1 | 7 | 4 | 6 | 2 | 0 | 0 | 0 |
| BRA | 1 | 86 | 5 | 7 | 12 | 38 | 14 | 5 | 5 | 0 | 0 |
| CAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CAR | 0 | 12 | 1 | 2 | 3 | 2 | 2 | 2 | 0 | 0 | 0 |
| CHI | 1 | 12 | 0 | 0 | 1 | 0 | 6 | 0 | 1 | 2 | 2 |
| COL | 2 | 23 | 1 | 3 | 3 | 3 | 6 | 3 | 2 | 0 | 2 |
| COR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CUB | 0 | 6 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ECU | 0 | 8 | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 2 | 0 |
| ELS | 0 | 8 | 0 | 0 | 0 | 2 | 5 | 0 | 0 | 1 | 0 |
| GUT | 1 | 9 | 0 | 0 | 0 | 0 | 4 | 2 | 1 | 2 | 0 |
| HAI | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| HON | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| MEX | 0 | 64 | 4 | 5 | 14 | 15 | 25 | 1 | 0 | 0 | 0 |
| NIC | 0 | 4 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| PAN | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| PAR | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| PER | 0 | 19 | 2 | 1 | 2 | 4 | 6 | 4 | 0 | 0 | 0 |
| URU | 1 | 4 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| USA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| VEN | 0 | 4 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| TOTAL | 8 | 296 | 15 | 23 | 47 | 74 | 82 | 24 | 13 | 11 | 7 |

Cuadro No.2
Casos de PFA notificados, tasa por 100,000 <15 años,
% de casos investigados dentro 48 horas, % con 1 muestra
Adecuada y % de unidades notificando semanalmente

| PAIS | Total 2002 | | Últimas 52 semanas (2002/25-2003/24) | | | | |
|--------------|-------------|-------------|--------------------------------------|-------------|--------------------|---------------------|------------------------------|
| | CASOS | TASA | CASOS | TASA | % INV, <48 hrs, | %1 Mues- tra+ | % Sitios Notifi- caron |
| ARG | 129 | 1,19 | 120 | 1,08 | 92 | 69 | 100 |
| BOL | 64 | 1,95 | 54 | 1,60 | 98 | 63 | 0 |
| BRA | 636 | 1,23 | 521 | 1,01 | 95 | 75 | 90 |
| CAN | NR | NR | NR | NR | NR | NR | NR |
| CAR | 22 | 1,00 | 27 | 1,23 | 100 | 59 | 100 |
| CHI | 115 | 2,67 | 108 | 2,51 | 92 | 84 | 96 |
| COL | 121 | 0,86 | 114 | 0,81 | 72 | 79 | 55 |
| COR | 29 | 2,38 | 15 | 1,23 | 100 | 87 | 0 |
| CUB | 37 | 0,83 | 23 | 0,51 | 96 | 100 | 96 |
| DOR | 36 | 1,12 | 27 | 0,80 | 100 | 78 | 91 |
| ECU | 43 | 1,00 | 43 | 0,99 | 70 | 93 | 84 |
| ELS | 116 | 5,08 | 103 | 4,47 | 71 | 85 | 61 |
| GUT | 72 | 1,58 | 76 | 1,67 | 91 | 91 | 44 |
| HAI | 12 | 0,38 | 11 | 0,34 | 73 | 36 | 40 |
| HON | 72 | 2,95 | 54 | 1,98 | 96 | 98 | 94 |
| MEX | 384 | 1,18 | 357 | 1,09 | 92 | 82 | 96 |
| NIC | 28 | 1,25 | 27 | 1,19 | 96 | 96 | 100 |
| PAN | 4 | 0,41 | 4 | 0,43 | 100 | 75 | 80 |
| PAR | 27 | 1,21 | 18 | 0,81 | 67 | 56 | 88 |
| PER | 96 | 1,12 | 78 | 0,91 | 100 | 90 | 99 |
| URU | 9 | 1,10 | 7 | 0,85 | 86 | 43 | 60 |
| USA | NR | NR | NR | NR | NR | NR | NR |
| VEN | 106 | 1,39 | 90 | 1,18 | 86 | 87 | 85 |
| Total | 2158 | 1,29 | 1877 | 1,12 | 90 | 80 | 82 |

+ Tomado dentro de los primeros 14 días del inicio de parálisis
 † Excluyendo Canadá y EUA NR - No reportes I.

Cuadro No. 3
Casos confirmados de poliomieltis
por semana de inicio

Hasta la semana 24

| PAIS | TOTAL 2002 | Acumulado | |
|--------------|---------------|-----------|----------|
| | | 2002 | 2003 |
| ARG | 0 | 0 | 0 |
| BOL | 0 | 0 | 0 |
| BRA | 0 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 0 | 0 | 0 |
| COL | 0 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 0 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 0 | 0 | 0 |
| HAI | 0 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 0 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 0 | 0 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 0 | 0 | 0 |

CAR Incluye informes de todos sus Países Miembros

Cuadro No. 4
Casos compatibles de poliomieltis
por semana de inicio

Hasta la semana 24

| PAIS | TOTAL 2002 | Acumulado | |
|--------------|---------------|-----------|----------|
| | | 2002 | 2003 |
| ARG | 0 | 0 | 0 |
| BOL | 2 | 1 | 0 |
| BRA | 1 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 1 | 0 | 0 |
| COL | 1 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 0 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 0 | 0 | 1 |
| HAI | 0 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 1 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 1 | 1 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 7 | 2 | 1 |

CAR Incluye informes de todos sus Países Miembros

LA POLIOMIELITIS HA SIDO ERRADICADA DE LAS AMÉRICAS
 El último caso con poliovirus salvaje fue detectado el 5 de septiembre de 1991, en Perú